Peptides
Sai Life Sciences offers a comprehensive, end-to-end peptide capability spanning discovery, development, and manufacturing. We bring deep expertise across diverse peptide modalities—delivering fully integrated programs that combine chemistry, biology, scale-up, and impurity synthesis under one roof.
Discovery Excellence
Our peptide discovery group provides a fully integrated drug discovery service, seamlessly combining:
- Design and synthesis of complex peptides
- Biology integration and screening support
- Impurity synthesis and analytical characterization
- Process development and early scale-up
We leverage state-of-the-art technologies, including automated solid-phase peptide synthesis (SPPS), advanced isolation techniques, and high-resolution purification platforms to ensure speed, quality, and reproducibility.
Our expertise spans a wide spectrum of peptide types:
-
Linear peptides
-
Macrocyclic peptides
-
Constrained peptides
-
Disulfide-bridged peptides
-
Bi- and tricyclic peptides
-
Peptide–drug conjugates (PDCs)
-
Oligopeptides and complex conjugates
Advancing CMC Capabilities
Sai Life Sciences is actively expanding its peptide CMC infrastructure to support seamless progression from discovery into development.
- Proven experience in liquid-phase synthesis of short peptides, delivered at scales exceeding 100 kg
- Ongoing investment in a Centre of Excellence for Peptide Research & Development at our Hyderabad campus
The upcoming Centre of Excellence (operational Q1 2027) will integrate cutting-edge peptide technologies to support:
- Process development and optimization
- Non-GMP batch production in the hundreds-of-grams scale
- Robust analytical and characterization workflows
Advancing CMC Capabilities
Sai Life Sciences is actively expanding its peptide CMC infrastructure to support seamless progression from discovery into development.
- Proven experience in liquid-phase synthesis of short peptides, delivered at scales exceeding 100 kg
- Ongoing investment in a Centre of Excellence for Peptide Research & Development at our Hyderabad campus
The upcoming Centre of Excellence (operational Q1 2027) will integrate cutting-edge peptide technologies to support:
- Process development and optimization
- Non-GMP batch production in the hundreds-of-grams scale
- Robust analytical and characterization workflows
GMP Manufacturing for Peptides
To complete our end-to-end offering, Sai Life Sciences plans to establish a dedicated GMP peptide manufacturing unit at our new Choutuppal site.
This facility will:
- Incorporate both solid- and liquid-phase manufacturing technologies
- Support peptide production at multiple tens-of-kilogram scale
- Enable scalable, regulatory-ready supply
The GMP unit is targeted to be operational by the end of 2027, strengthening our ability to support clients from early discovery through clinical and commercial supply.
- Fully integrated discovery-to-development platform
- Broad modality expertise across complex peptide architectures
- Flexible scale—from milligram libraries to multi-kilogram manufacturing
- Strategic investments in next-generation peptide R&D and GMP infrastructure
Our expanding peptide capabilities position us as a long-term partner for innovators advancing peptide therapeutics—from concept to clinic and beyond.